HORIZON EUROPE
Europeo
Expected Impact:The actions to be funded under this topic are expected to achieve the following:
a. contribute to one or more of IHI JU’s expected impacts linked to Specific Objective 1 as set out in the IHI JU SRIA, i.e.:
patients benefit from preventive treatment or early disease intervention before onset of symptoms;prevention and early diagnosis of disease combined with better understanding of the mechanisms involved, leading to the development of more cost-effective strategies;patients benefitting from improved healthcare through regular monitoring of critical parameters using validated tools;development of new vaccine strategies targeted to specific sub-populations;increased preparedness of EU healthcare systems for disease outbreaks. b. contribute to strengthening the competitiveness of the EU’s health industry, via increased economic activity in the development of health technologies, in particular, integrated health solutions, thus fostering European technological leadership and the digital transformation of our societies.
The actions are expected to contribute to EU programmes, initiatives and policies such as the European Green Deal...
ver más
Expected Impact:The actions to be funded under this topic are expected to achieve the following:
a. contribute to one or more of IHI JU’s expected impacts linked to Specific Objective 1 as set out in the IHI JU SRIA, i.e.:
patients benefit from preventive treatment or early disease intervention before onset of symptoms;prevention and early diagnosis of disease combined with better understanding of the mechanisms involved, leading to the development of more cost-effective strategies;patients benefitting from improved healthcare through regular monitoring of critical parameters using validated tools;development of new vaccine strategies targeted to specific sub-populations;increased preparedness of EU healthcare systems for disease outbreaks. b. contribute to strengthening the competitiveness of the EU’s health industry, via increased economic activity in the development of health technologies, in particular, integrated health solutions, thus fostering European technological leadership and the digital transformation of our societies.
The actions are expected to contribute to EU programmes, initiatives and policies such as the European Green Deal, Europe’s Beating Cancer Plan, the EU Mission on Cancer, the European Virtual Human Twins Initiative, the European Health Emergency Preparedness and Response Authority (HERA), the European Commission’s proposal for the European Health Data Space (EHDS), and the EU Artificial Intelligence Act1, where relevant.
1 EU Artificial Intelligence Act | Up-to-date developments and analyses of the EU AI Act
Expected Outcome:Applicants must define the outcomes expected to be achieved by the project, ensuring that they contribute to at least one of IHI JU’s potential outputs linked to the IHI JU’s Specific Objective 1 ‘contribute towards a better understanding of the determinants of health and priority disease areas’, as set out in the IHI JU Strategic Research and Innovation Agenda (SRIA).
Actions (projects) to be funded under this topic must deliver results that address public health needs and support the development of future health innovations that are safe, people-centred, effective, cost-effective and affordable for patients and for health care systems.
The expected outcomes may cover the entire spectrum of care and may be health technologies centred around disease areas and/or key themes such as prevention, precision diagnostics, personalised medicine, and chronic disease management. They may also include solutions for key enablers such as digital data and solutions, artificial intelligence (AI), regulatory science, greener and more sustainable healthcare, and implementation science1.
1 In the context of IHI, ‘implementation science’ refers to the development and piloting of methods and strategies that facilitate the uptake of evidence-based practice and research outcomes into regular use (e.g. translation of results, uptake, scale-up, piloting in healthcare).
Scope:With a view to harnessing new science and technologies, this topic aims to fund pre-competitive research and innovation for novel tools, methods, technologies etc. that will foster the development of health innovations to prevent, intercept, diagnose, treat, and manage diseases and enable recovery more efficiently.
Accordingly, applicants must assemble a collaborative public-private partnership consortium reflecting the integrative and cross-sectoral nature of IHI JU, that is capable of addressing the challenge(s) and scope of the IHI JU Specific Objective 1 ‘contribute towards a better understanding of the determinants of health and priority disease areas’, as defined in IHI JU’s legal basis1 and described in more detail in the IHI JU SRIA2:
Applicants should consider the following points in their proposals:
a. address an unmet public health need based on at least one of the below:
the high burden of the disease for patients and/or society due to its severity and/or the number of people affected by it;the high economic impact of the disease for patients and society;the transformational nature of the potential results on innovation processes where projects are not focussed on individual disease areas (e.g. health data analytics). b. demonstrate the ability to translate research into innovative solutions that can be integrated/implemented into the healthcare ecosystem (taking into consideration the fragmented nature of European healthcare systems) and/or in industrial processes.
When applicable, proposals should consider relevant aspects of patient-centricity, with the help of the most suitable health technologies and/or social innovations, including open science, and taking demographic trends into account as relevant.
If applicable, applicants are expected to consider the potential regulatory impact of the anticipated project’s outputs, and, as relevant, develop a regulatory strategy and interaction plan for generating appropriate evidence and for engaging with regulators and other bodies in a timely manner, e.g. EU national competent authorities, notified bodies for medical devices and in-vitro diagnostic devices, health technology assessment (HTA) agencies, and the European Medicines Agency (EMA) through existing opportunities for regulatory support services, such as the Innovation Task Force and qualification advice.
As relevant, consideration should also be given to the Health Data Access Bodies that will be established under the forthcoming European Health Data Space Regulation3 in the context of secondary use of data.
Applicants should consider relevant existing initiatives/projects to ensure synergies and complementarities and avoid unnecessary overlap and duplication of efforts. The proposal should include a plan on how to synergise with these initiatives.
1 Article 115 of the Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe
2 https://www.ihi.europa.eu/sites/default/files/flmngr/IHI_Strategic_Research_and_Innovation_Agenda_3.pdf
3 https://www.europarl.europa.eu/doceo/document/TA-9-2024-0331_EN.pdf
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Gastos relacionados con el personal que trabaja directamente en el proyecto basado en las horas efectivas dedicadas, basado en el coste empresa y ratios fijos para determinados empleados como los dueños de la compañía.
Pagos a terceros externos para realizar tareas específicas que no pueden ser realizadas por los beneficiarios del proyecto.
Incluyen la adquisición de equipos, amortizaciones, material, licencias u otros bienes y servicios necesarios para la ejecución del proyecto
Gastos diversos como costes financieros, certificados de auditoría o participación en eventos no cubiertos por otras categorías
Gastos generales no asignables directamente al proyecto (como electricidad, alquiler u oficina), calculados como un 25% fijo sobre los costes directos elegibles (excepto subcontratación).
Características de la financiación
Información adicional de la convocatoria
Otras ventajas
